Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast

Pharmacotherapy

Volumn 21, Issue 6, 2001, Pages 653-660

  Zussman, Barry D ^a   Davie, Christopher C ^a   Kelly, John ^a   Murdoch, Robert D ^a   Clark, David J ^a   Schofield, J Paul ^a   Walls, Christine ^a   Birrell, Claire ^a   Webber, Dawn ^a   Quinlan, Judith ^a   Ritchie, Sally Y ^a   Carr, Alison ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ANTACID AGENT; CILOMILAST; MYLANTA; PHOSPHODIESTERASE IV INHIBITOR; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FOOD DRUG INTERACTION; HEADACHE; HUMAN;

EID: 0034990671     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.7.653.34569     Document Type: Article

References (12)

1. Ariflo (SB 207499), a second generation phosphodiesterase inhibitor for the treatment of asthma COPD: From concept to clinic
2. Phosphodiesterase isoenzymes: Molecular targets for novel antiasthma agents
3. Relationships between adenosine cyclic nucleotides, and xanthines in asthma
4. Multiple mechanisms of xanthine actions on airway reactivity
5. Effects of rolipram on responses to acute chronic antigen exposure in monkeys
6. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: Correlation between function interaction with a high-affinity rolipram binding site
7. 3H] rolipram binding activity their relationship to emetic behavior in the ferret
8. The safety tolerability of Ariflo (SB 207499), a novel and selective phosphodiesterase inhibitor in healthy male volunteers
9. 4 inhibitor, has a favourable metabolic profile with low potential for drug-drug interactions
10. 4 inhibitor. First demonstration of efficacy in patients with COPD
11. Antacids revisited: A review of their clinical pharmacology recommended therapeutic use
12. Drug interactions with antacids. Mechanisms clinical significance